A5016779179- Diabetes Treatment and Management
- Diabetes Management and Research
- Medication Adherence and Compliance
- Chronic Disease Management Strategies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Education
- Botulinum Toxin and Related Neurological Disorders
- Metabolism, Diabetes, and Cancer
- Cannabis and Cannabinoid Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pharmaceutical studies and practices
- Pharmaceutical Practices and Patient Outcomes
- Obesity, Physical Activity, Diet
- Primary Care and Health Outcomes
- Obesity and Health Practices
- Neurological disorders and treatments
- Stroke Rehabilitation and Recovery
- Cerebral Palsy and Movement Disorders
- Forensic Toxicology and Drug Analysis
- Diet and metabolism studies
- Nutritional Studies and Diet
- Pharmacology and Obesity Treatment
- Nutrition and Health in Aging
- Statistical Methods in Clinical Trials
Université Laval
2023-2025
Ipsen (United States)
2022-2024
Ipsen (France)
2023
Novo Nordisk (United States)
2011-2020
Sanofi (United States)
2019-2020
Novo Nordisk (United Kingdom)
2010-2018
Ibero American University
2016
Novo Nordisk (Denmark)
2011-2015
AstraZeneca (United States)
2009
Thomson Reuters (United States)
2009
Aims: This retrospective observational study examined the association between International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM)‐coded outpatient hypoglycaemic events and fall‐related fractures in Medicare‐covered patients with type 2 diabetes. Methods: Data were derived from healthcare claims for individuals employer‐sponsored Medicare supplemental insurance. The period consisted two consecutive 1‐year periods; baseline (1 April 2008 to 31 March 2009)...
Objective To determine the prevalence of obesity and its related comorbidities among patients being actively managed at a US academic medical centre, to examine frequency formal diagnosis obesity, via International Classification Diseases, Ninth Revision (ICD-9) documentation with body mass index (BMI) ≥30 kg/m 2 . Design The electronic health record system Cleveland Clinic was used create cross-sectional summary meeting minimum primary care physician visit requirements. Eligible were...
This retrospective study examined the association between ICD-9-CM-coded outpatient hypoglycemic events (HEs) and acute cardiovascular (ACVEs), i.e., myocardial infarction, coronary artery bypass grafting, revascularization, percutaneous intervention, incident unstable angina, in patients with type 2 diabetes.Data were derived from healthcare claims for individuals employer-sponsored primary or Medicare supplemental insurance. A baseline period (30 September 2006 to 30 2007) was used...
To compare the prevalence of diabetes-related complications and comorbidities, clinical characteristics, glycemic control, treatment patterns in patients with type 2 diabetes (T2D) within a large integrated healthcare system 2008 vs 2013.An electronic health record was used to create cross-sectional summary all T2D as on 1 July 2013. Differences between two data sets were assessed after adjusting for age, gender, race, household income.In 2013, 24 493 41 582 identified, respectively, which...
We compared methods to control bias and confounding in observational studies including inverse probability weighting (IPW) stabilized IPW (sIPW). These often require iteration post-calibration achieve covariate balance. In comparison, entropy balance (EB) optimizes a priori by calibrating weights using the target's moments as constraints.We measured empirically simulation absolute standardized mean difference (ASMD), (AB), root square error (RMSE), investigating two scenarios: size of...
Blood–brain barrier (BBB) alterations contribute to stress vulnerability and the development of depressive behaviors. In contrast, neurovascular adaptations underlying resilience remain unclear. Here we report that high expression astrocytic cannabinoid receptor 1 (CB1) in nucleus accumbens (NAc) shell, particularly end-feet ensheathing blood vessels, is associated with during chronic social adult male mice. Viral-mediated overexpression Cnr1 astrocytes NAc shell results baseline anxiolytic...
Readmission is costly among patients with type 2 diabetes (T2DM) in Medicare Advantage Prescription Drug Plans; identifying high-risk necessary for targeting reduction programs. The objective of this study was to develop a claims-based algorithm predict all-cause 30 day readmission T2DM.This used administrative data from 1 January 2012 through 31 2014. cohort included hospitalized T2DM patients, aged 18-90 ≥12 months' continuous enrollment before an unplanned hospital admission and ≥1 month...
This study was conducted to compare adherence and persistence of patients initiating basal insulin therapy with Levemir FlexPen versus those NPH via vial syringe.Data were gathered from a large US retrospective claims database, included type 2 diabetes that initiated either or in vials. Patients defined as adherent if they had medication possession ratio (MPR) ≥80% the 12-month follow-up period persistent no gaps period.After controlling for confounders using logistic regression, 39% higher...
Previous studies have found higher rates of adherence in patients with type 2 diabetes mellitus (T2DM) using insulin pens compared to vial and syringe administration; however, little evidence is available support this observation elderly patients. This was a retrospective claims database analysis predominantly Medicare Advantage Prescription Drug (MAPD) insurance population consisting 3172 insulin-naïve T2DM who initiated basal pre-filled or ('vial'). The index date defined by the first...
Objective:To estimate and compare the annual direct healthcare cost among Type 1 (T1DM) 2 (T2DM) diabetes patients using two estimation methods: (1) DM-attributable (2) all cause case–control cost.Research design methods:An administrative claims cohort study HealthCore Integrated Research Database (HIRD®) identified T1DM T2DM age ≥18 <65 years between 1/1/2006 – 12/31/2006. DM (cases) were matched 1:1 with non-DM (controls) by age, gender, state, commercial plan type (HMO, PPO, POS). All had...
Abstract Aim Liraglutide ( LIRA ) once‐daily has provided greater A1C reductions than either exenatide EXEN twice‐daily or sitagliptin SITA in head‐to‐head trials. The objective of this analysis is to compare the real‐world clinical effectiveness these agents USA . Methods Using IMS Health (Alexandria, VA , USA) integrated claims database, outcomes patients aged ≥18 years with type 2 diabetes T2D who initiated (including /metformin) were retrospectively compared. Patients included had ≥1...
To examine the association of obesity with healthcare resource utilization and costs in a Medicare population.This study was retrospective cohort using Humana Advantage (MA) claims data. Body mass index (BMI) assessed ICD-9-CM status codes (V85 hierarchy) that have been validated data source to classify patients into BMI categories: normal (N), overweight (Ow), obese class I (ObI), II (ObII), III (ObIII). Healthcare (HRU) were determined based on Descriptive statistics used baseline...
This retrospective cohort study evaluated associations of race/ethnicity and gender with outcomes diabetes complications severity, health care resource utilization (HRU), costs among Medicare Advantage plan members type 2 (T2DM). Medical pharmacy claims were for 333,576 continuously enrolled from January 1, 2010, to December 31, 2011, aged 18-89 years, ≥1 primary diagnosis medical claim, or ≥2 a secondary T2DM (International Classification Diseases, Ninth Revision, Clinical Modification code...
Objective: The objective of this study was to estimate the incremental long-term costs associated with T2DM attributable vascular diseases. Research Design and Methods: This retrospective cohort identified newly diagnosed (incident) patients in 2007 (baseline 01/01/2006) using HealthCore Integrated Database, a repository nationally representative claims data. Incident were 1:1 exact matched on age, gender other factors interest non-DM patients, followed until earlier 8 follow-up years or...
To examine the association of obesity with healthcare resource utilization (HRU) and costs among commercially insured individuals.This retrospective observational cohort study used administrative claims from 1 January 2007 to December 2013. The ICD-9-CM status codes (V85 hierarchy) 2008 2012 classified body mass index (BMI) into World Health Organizations' BMI categories. date first observed code was defined as continuous eligibility for one year pre- post- ensured. Post-index determined...
This study evaluated relationships between glycaemic control, body mass index (BMI), comorbidities and pharmacological treatment in patients with type 2 diabetes mellitus (T2D).
Objective To explore trends in demographics, comorbidities, anti-diabetic drug usage, and healthcare utilization costs patients with newly-diagnosed type 2 diabetes mellitus (T2DM) using a large US claims database.Methods For the years 2007 2012, Truven Health Marketscan Research Databases were used to identify adults T2DM continuous 12-month enrollment prescription benefits. Variables examined included patient inpatient patterns, (inpatient outpatient), costs, claim patterns.Results Despite...
Background The study examined the prevalence of early treatment revisions after glycosylated hemoglobin (HbA1c) ≥9.0% (75 mmol/mol) and estimated impact on glycemic control, diabetic complications, costs. Research design methods A retrospective cohort administrative claims data plan members with type 2 diabetes HbA1c was completed. Treatment revision identified as addition or switch. Glycemic control measured during 6–12 months following first qualifying laboratory result. Complications...